Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist prescribed as an ophthalmic solution to treat the signs and symptoms of dry eye disease by inhibiting inflammatory cell binding.… Read more









Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist prescribed as an ophthalmic solution to treat the signs and symptoms of dry eye disease by inhibiting inflammatory cell binding. To support the rigorous quality control and safety assessment of this active pharmaceutical ingredient, laboratories rely on a comprehensive range of Lifitegrast reference standards, including structurally characterized impurities, degradation products, and stable isotope labelled compounds. These specialized materials are essential for conducting precise impurity profiling and the development and validation of sensitive analytical methods, such as HPLC and LC-MS. By utilizing these standards, researchers can reliably identify and quantify impurities formed through pathways like oxidation and hydrolysis, ensuring consistent product quality. These tools facilitate adherence to regulatory requirements throughout the drug lifecycle, enabling laboratories to maintain high analytical accuracy and confirm that the final pharmaceutical product meets established safety and performance benchmarks.